Search / Trial NCT00002201

A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients

Launched by ABBOTT · Aug 30, 2001

Trial Information

Current as of December 06, 2024

Completed

Keywords

Drug Therapy, Combination Hiv Protease Inhibitors Ritonavir Nelfinavir Anti Hiv Agents

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Patients must have:
  • Documentation of a positive ELISA test for HIV confirmed by immunoblot, or a positive HIV RNA test using the Roche PCR assay, or the Chiron bDNA assay.
  • HIV RNA measurement of \> 5,000 copies/ml within 3 weeks of baseline visit.
  • Signed, informed consent from parent or legal guardian for patients less than 18 years of age.
  • Access to a refrigerator for storing study drug.
  • Prior Medication:
  • Allowed:
  • Anti-HIV therapy other than protease inhibitor therapy.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following conditions or symptoms are excluded:
  • Evidence of acute infection, as measured by vital signs, physical examination, 12-lead electrocardiogram and laboratory assessments.
  • Condition that may obscure the proper observation of the safety or activity of the treatment regimens.
  • Concurrent Medication:
  • Excluded:
  • Midazolam, alprazolam, clorazepate, diazepam, estazolam, flurazepam, triazolam, zolpidem, quinidine, amiodarone, encainide, flecainide, propafenone, bepridil, terfenadine, astemizole, cisapride, bupropion, clozapine, rifabutin, meperidine, propoxyphene, piroxicam, pimozide, ergotamine, dihydroergotamine, and rifampin.
  • Anti-retroviral therapy initiated prior to study entry.
  • Any other medication, including over-the-counter medicine and alcohol, taken without the permission of the primary investigator.
  • Patients with the following prior conditions are excluded:
  • History of significant drug hypersensitivity.
  • History of psychiatric illness that would preclude compliance with the protocol.
  • Prior enrollment in this study.
  • Prior Medication:
  • Excluded:
  • Investigational drugs within 30 days prior to drug administration.
  • Prior treatment with licensed or investigational HIV protease inhibitor.
  • 1. Active substance abuse.
  • * Positive urine screen for recreational drugs. NOTE:
  • The presence of cannabis is not exclusionary unless the investigator believes its use will interfere with patient compliance.

About Abbott

Abbott is a global healthcare company dedicated to improving lives through innovative medical technologies, diagnostics, nutrition, and branded generic pharmaceuticals. With a commitment to advancing health and wellness, Abbott conducts clinical trials to evaluate the safety and efficacy of its diverse portfolio of products, which span multiple therapeutic areas, including cardiovascular, diabetes care, and neurology. The company employs rigorous research methodologies and collaborates with healthcare professionals and institutions worldwide to ensure the highest standards of clinical integrity and patient safety. Abbott's mission is to deliver impactful solutions that enhance patient outcomes and contribute to the advancement of global healthcare.

Locations

Baltimore, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials